Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety study of TEG001 in relapsed/refractory AML, high-risk MDS, or multiple myeloma
NL-OMON47707Phase 1Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TEG001 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), sponsored by University Medical Center Utrecht. Primary endpoint: Dose-limiting toxicities. Started Jul 2018; status: recruiting.
02
Drugs
TEG001
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47707.